ADPKD is the most common hereditary kidney disease, affecting 1 in 400 to 1000 individuals and accounting for 4% of end-stage renal disease in the United States and 8-10% in Europe. The condition is characterized by progressive development of kidney cysts with kidney enlargement and associated loss of kidney function. High blood pressure and cardiovascular disease are common in patients with ADPKD. Although the condition is often thought to affect primarily adults, it is clear that the disease can be present in the fetus and young children. This study is designed to determine if treatment with the medicines, pravastatin and lisinopril, can slow the progression of kidney and heart disease when initiated early in life in patients with ADPKD. The goal of this randomized double-blind placebo-controlled trial is to determine whether treatment with the 3-hydroxy-3- methylglutaryl coenzyme A (HMG coA) inhibitor pravastatin will delay the progression of renal and cardiovascular disease over a three-year period in children and young adults with autosomal dominant polycystic kidney disease (ADPKD) who are receiving angiotensin converting enzyme inhibitors. The primary endpoint of the study will be achieved in subjects with 20% or greater change over the three-year interval in any or all of the following four endpoints: 1) total renal volume as assessed by MRI; 2) left ventricular mass index as assessed by MRI; 3) urinary albumin excretion; and 4) endothelial-dependent vasodilation as assessed by brachial ultrasonography. This study will involve pediatric subjects because we believe that early intervention is critical if we are to ameliorate the morbidity and mortality associated with this condition. If pravastatin is shown to be effective in ameliorating progression of renal and cardiovascular disease in this study, routine management of affected patients will be drastically altered. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK058793-07
Application #
7265190
Study Section
Clinical and Integrative Cardiovascular Sciences Study Section (CICS)
Program Officer
Moxey-Mims, Marva M
Project Start
2001-04-01
Project End
2010-07-31
Budget Start
2007-08-01
Budget End
2008-07-31
Support Year
7
Fiscal Year
2007
Total Cost
$547,305
Indirect Cost
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Nowak, Kristen L; Cadnapaphornchai, Melissa A; Chonchol, Michel B et al. (2016) Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease. Am J Nephrol 44:171-8
Cadnapaphornchai, Melissa A (2013) Hypertension in children with autosomal dominant polycystic kidney disease (ADPKD). Curr Hypertens Rev 9:21-6
Cadnapaphornchai, Melissa A; Masoumi, Amirali; Strain, John D et al. (2011) Magnetic resonance imaging of kidney and cyst volume in children with ADPKD. Clin J Am Soc Nephrol 6:369-76
Cadnapaphornchai, Melissa A; George, Diana M; Masoumi, Amirali et al. (2011) Effect of statin therapy on disease progression in pediatric ADPKD: design and baseline characteristics of participants. Contemp Clin Trials 32:437-45
Cadnapaphornchai, Melissa A; McFann, Kim; Strain, John D et al. (2009) Prospective change in renal volume and function in children with ADPKD. Clin J Am Soc Nephrol 4:820-9
Schrier, Robert W (2009) Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 20:1888-93
Cadnapaphornchai, Melissa A; McFann, Kim; Strain, John D et al. (2008) Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension. Kidney Int 74:1192-6
Cadnapaphornchai, Melissa A; Fick-Brosnahan, Godela M; Duley, Irene et al. (2005) Design and baseline characteristics of participants in the study of antihypertensive therapy in children and adolescents with autosomal dominant polycystic kidney disease (ADPKD). Contemp Clin Trials 26:211-22